Nanoemulsions as novel oral carriers of stiripentol: Insights into the protective effect and absorption enhancement

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 4937-4946

  Lu, Rong ^a   Liu, Shan ^a   Wang, Qilin ^a   Li, Xia ^a,b  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Bioavailability; Intestinal permeability; Nanoemulsions; Stability; Stiripentol

Indexed keywords

MEDIUM CHAIN TRIACYLGLYCEROL; STIRIPENTOL; 1,3 DIOXOLANE DERIVATIVE; DRUG CARRIER; EMULSION; NANOPARTICLE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CACO 2 CELL LINE; CONTROLLED STUDY; DIFFUSION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; ENCAPSULATION; INTESTINE MUCOSA PERMEABILITY; MAXIMUM PLASMA CONCENTRATION; NANOEMULSION; NONHUMAN; PARTICLE SIZE; PLASMA HALF LIFE; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSMISSION ELECTRON MICROSCOPY; ULTRASOUND; ANIMAL; BIOAVAILABILITY; CHEMISTRY; EMULSION; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS;

NES; RATTUS;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; DIOXOLANES; DRUG CARRIERS; DRUG STABILITY; EMULSIONS; NANOPARTICLES; RATS;

EID: 84981722657     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/ijn.s87471     Document Type: Article

References (35)

1. Chiron C. Stiripentol. Expert Opin Investig Drugs. 2005;14(7):905–911.
2. Strzelczyk A, Kortland LM, Knake S, Rosenow F. Stiripentol for the treatment of super-refractory status epilepticus. Acta Neurol Scand. Epub 2015.
3. Sada N, Lee S, Katsu T, Otsuki T, Inoue T. Epilepsy treatment. Targeting LDH enzymes with a stiripentol analog to treat epilepsy. Science. 2015;347(6228):1362–1367.
4. Zhang X, Wang H, Zhang T, Zhou X, Wu B. Exploring the potential of self-assembled mixed micelles in enhancing the stability and oral bioavailability of an acid-labile drug. Eur J Pharm Sci. 2014;62:301–308.
5. Zhang X, Sun N, Wu B, Lu Y, Guan T, Wu W. Physical characterization of lansoprazole/PVP solid dispersion prepared by fluid-bed coating technique. Powder Technol. 2008;182(3):480–485.
6. Yun F, Kang A, Shan J, et al. Preparation of osthole-polymer solid dispersions by hot-melt extrusion for dissolution and bioavailability enhancement. Int J Pharm. 2014;465(1–2):436–443.
7. Zhang X, Wu D, Lai J, Lu Y, Yin Z, Wu W. Piroxicam/2-hydroxypropyl-beta-cyclodextrin inclusion complex prepared by a new fluid-bed coating technique. J Pharm Sci. 2009;98(2):665–675.
8. Liu H, Yang G, Tang Y, et al. Physicochemical characterization and pharmacokinetics evaluation of beta-caryophyllene/beta-cyclodextrin inclusion complex. Int J Pharm. 2013;450(1–2):304–310.
9. Tian Z, Yi Y, Yuan H, et al. Solidification of nanostructured lipid carriers (NLCs) onto pellets by fluid-bed coating: Preparation, in vitro characterization and bioavailability in dogs. Powder Technol. 2013;247:120–127.
10. Lei Y, Qi J, Nie S, et al. Solid self-nanoemulsifying cyclosporine A pellets prepared by fluid-bed coating: stability and bioavailability study. J Biomed Nanotechnol. 2012;8(3):515–521.
11. Bachar M, Mandelbaum A, Portnaya I, et al. Development and characterization of a novel drug nanocarrier for oral delivery, based on self-assembled beta-casein micelles. J Control Release. 2012;160(2):164–171.
12. Yuan H, Chen CY, Chai GH, Du YZ, Hu FQ. Improved transport and absorption through gastrointestinal tract by PEGylated solid lipid nanoparticles. Mol Pharm. 2013;10(5):1865–1873.
13. Zhang X, Chen G, Zhang T, Ma Z, Wu B. Effects of PEGylated lipid nanoparticles on the oral absorption of one BCS II drug: a mechanistic investigation. Int J Nanomedicine. 2014;9:5503–5514.
14. Xu W, Ling P, Zhang T. Polymeric micelles, a promising drug delivery system to enhance bioavailability of poorly water-soluble drugs. J Drug Deliv. 2013;2013:1–15.
15. Malathi S, Nandhakumar P, Pandiyan V, Webster TJ, Balasubramanian S. Novel PLGA-based nanoparticles for the oral delivery of insulin. Int J Nanomedicine. 2015;10:2207–2218.
16. Tariq M, Alam MA, Singh AT, Iqbal Z, Panda AK, Talegaonkar S. Biodegradable polymeric nanoparticles for oral delivery of epirubicin: in vitro, ex vivo, and in vivo investigations. Colloids Surf B Biointerfaces. 2015;128:448–456.
17. Niu M, Lu Y, Hovgaard L, Wu W. Liposomes containing glycocholate as potential oral insulin delivery systems: preparation, in vitro characterization, and improved protection against enzymatic degradation. Int J Nanomedicine. 2011;6:1155–1166.
18. Zhang X, Qi J, Lu Y, He W, Li X, Wu W. Biotinylated liposomes as potential carriers for the oral delivery of insulin. Nanomedicine. 2014;10(1):167–176.
19. Porter CJ, Kaukonen AM, Boyd BJ, Edwards GA, Charman WN. Susceptibility to lipase-mediated digestion reduces the oral bioavailability of danazol after administration as a medium-chain lipid-based microemulsion formulation. Pharm Res. 2004;21(8):1405–1412.
20. Feeney OM, Williams HD, Pouton CW, Porter CJ. ‘Stealth’ lipid-based formulations: Poly(ethylene glycol)-mediated digestion inhibition improves oral bioavailability of a model poorly water soluble drug. J Control Release. 2014;192:219–227.
21. Zhang X, Wang H, Ma Z, Wu B. Effects of pharmaceutical PEGylation on drug metabolism and its clinical concerns. Expert Opin Drug Metab Toxicol. 2014;10(12):1691–1702.
22. Zhou X, Zhang X, Ye Y, et al. Nanostructured lipid carriers used for oral delivery of oridonin: an effect of ligand modification on absorption. Int J Pharm. 2015;479(2):391–398.
23. Nozawa T, Imai T. Prediction of human intestinal absorption of the prodrug temocapril by in situ single-pass perfusion using rat intestine with modified hydrolase activity. Drug Metab Dispos. 2011;39(7):1263–1269.
24. Zhang X, Zhang T, Zhou X, et al. Enhancement of oral bioavailability of tripterine through lipid nanospheres: preparation, characterization, and absorption evaluation. J Pharm Sci. 2014;103(6):1711–1719.
25. He C, Yin L, Tang C, Yin C. Size-dependent absorption mechanism of polymeric nanoparticles for oral delivery of protein drugs. Biomaterials. 2012;33(33):8569–8578.
26. Gaumet M, Gurny R, Delie F. Localization and quantification of biodegradable particles in an intestinal cell model: The influence of particle size. Eur J Pharm Sci. 2009;36(4–5):465–473.
27. Sun D, Wei X, Xue X, et al. Enhanced oral absorption and therapeutic effect of acetylpuerarin based on D-alpha-tocopheryl polyethylene glycol 1000 succinate nanoemulsions. Int J Nanomedicine. 2014;9:3413–3423.
28. Zhao L, Wei Y, Fu J, Huang Y, He B, Zhou Y. Nanoemulsion improves the oral bioavailability of baicalin in rats: in vitro and in vivo evaluation. Int J Nanomedicine. 2013;8:3769–3779.
29. Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007;6(3):231–248.
30. He YL, Murby S, Warhurst G, et al. Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of poly(ethylene glycol) and D-peptides. J Pharm Sci. 1998;87(5):626–633.
31. Qian C, Decker EA, Xiao H, McClements DJ. Nanoemulsion delivery systems: influence of carrier oil on beta-carotene bioaccessibility. Food Chem. 2012;135(3):1440–1447.
32. Trevaskis NL, Charman WN, Porter CJ. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Del Rev. 2008;60(6):702–716.
33. You X, Xing Q, Tuo J, Song W, Zeng Y, Hu H. Optimizing surfactant content to improve oral bioavailability of ibuprofen in microemulsions: just enough or more than enough? Int J Pharm. 2014;471(1–2):276–284.
34. Lindmark T, Kimura Y, Artursson P. Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in Caco-2 cells. J Pharmacol Exp Ther. 1998;284(1):362–369.
35. Zakeri-Milani P, Valizadeh H, Tajerzadeh H, et al. Predicting human intestinal permeability using single-pass intestinal perfusion in rat. J Pharm Pharm Sci. 2007;10(3):368–379.